StockData
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. (TARS) stock

TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/303% below fair value
$73.01−4.66 (-6.00%)

Close on Nov 20, 2026Market cap $3.20BP/E –Yield 0.00%

Tarsus Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Tarsus Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was $56.00M. For fiscal 2025 it was -$22.31M. The highest annual figure on record is $3.16M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$22.31M–
FY2024Dec 31, 2024-$84.59M–
FY2023Dec 31, 2023-$119.00M–
FY2022Dec 31, 2022-$49.54M-1666.6%
FY2021Dec 31, 2021$3.16M–
FY2020Dec 31, 2020-$21.59M–
FY2019Dec 31, 2019-$3.85M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$57.15M–
Q1 FY2026Mar 31, 2026-$30.47M–
Q4 FY2025Dec 31, 2025$12.97M–
Q3 FY2025Sep 30, 2025$16.35M–
Q2 FY2025Jun 30, 2025-$30.39M–
Q1 FY2025Mar 31, 2025-$21.24M–
Q4 FY2024Dec 31, 2024-$22.25M–
Q3 FY2024Sep 30, 2024-$8.93M–
Q2 FY2024Jun 30, 2024-$15.44M–
Q1 FY2024Mar 31, 2024-$37.96M–
Q4 FY2023Dec 31, 2023-$39.34M–
Q3 FY2023Sep 30, 2023-$32.74M–
Q2 FY2023Jun 30, 2023-$24.61M–
Q1 FY2023Mar 31, 2023-$22.31M–
Q4 FY2022Dec 31, 2022-$11.00M–
Q3 FY2022Sep 30, 2022-$18.71M-367.6%
Q2 FY2022Jun 30, 2022-$4.38M-121.3%
Q1 FY2022Mar 31, 2022-$15.45M–
Q4 FY2021Dec 31, 2021-$12.40M–
Q3 FY2021Sep 30, 2021$6.99M–
Q2 FY2021Jun 30, 2021$20.54M–
Q1 FY2021Mar 31, 2021-$11.97M–
Q4 FY2020Dec 31, 2020-$9.96M–
Q3 FY2020Sep 30, 2020-$6.71M–
Q2 FY2020Jun 30, 2020-$2.89M–
Q1 FY2020Mar 31, 2020-$2.03M–
Q4 FY2019Dec 31, 2019-$830.00K–

More Tarsus Pharmaceuticals figures

See a number that looks wrong?